Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LEXICON PHARMACEUTICALS, INC. (LXRX)

Lexicon Q1 net loss narrows to $1.0 million from $25.3 million on $21.1 million revenue

Positive Impact 3 of 5 earnings Written later

Lexicon Pharmaceuticals reported first quarter 2026 results, with total revenues of $21.1 million, including $20.0 million of development milestone revenue from Novo Nordisk, compared with $1.3 million a year earlier. The net loss narrowed to $1.0 million, or less than $0.01 per share, from $25.3 million, or $0.07 per share. The company also disclosed a $100 million Hercules Capital loan facility, which repaid its prior Oxford Finance loan.

Key points

  • Total revenues were $21.1 million for Q1 2026, versus $1.3 million in Q1 2025; net product revenue from INPEFA was $1.1 million
  • Research and development expenses fell to $12.8 million from $15.3 million, and SG&A expenses fell to $9.2 million from $11.6 million
  • Cash, investments and restricted cash were $199.7 million at March 31, 2026, up from $125.2 million at December 31, 2025, reflecting $96.5 million in net proceeds from a February 2026 stock sale
  • In May 2026 Lexicon announced a $100 million Hercules Capital loan facility; an initial $55 million tranche repaid its Oxford Finance loan

The filing

CompanyLEXICON PHARMACEUTICALS, INC. (LXRX)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:31 AM ET
Accession number0001062822-26-000098

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.